Nuveen LLC Buys New Shares in GSK PLC Sponsored ADR $GSK

Key Points

• Nuveen LLC invested approximately $1.46 million in GSK PLC Sponsored ADR by purchasing 37,584 shares during the first quarter.
• GSK reported earnings per share (EPS) of $1.23 for the last quarter, exceeding estimates of $1.12, along with revenues of $10.64 billion.
• The company's quarterly dividend is set at $0.4206, with a dividend yield of 4.2% and a payout ratio of 77.78%.

Nuveen LLC bought a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 37,584 shares of the pharmaceutical company's stock, valued at approximately $1,456,000.

Other institutional investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its position in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares in the last quarter. Costello Asset Management INC bought a new position in GSK during the 1st quarter valued at approximately $31,000. Richardson Financial Services Inc. increased its position in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after buying an additional 472 shares in the last quarter. Olde Wealth Management LLC bought a new position in GSK during the 1st quarter valued at approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC increased its position in GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock valued at $39,000 after buying an additional 852 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GSK shares. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average target price of $37.38.

GSK Stock Up 0.0%

GSK traded up $0.02 during trading on Thursday, hitting $39.38. 1,673,370 shares of the company's stock traded hands, compared to its average volume of 5,071,661. The company's 50 day simple moving average is $38.46 and its two-hundred day simple moving average is $38.28. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.19. The stock has a market capitalization of $80.20 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 1.72 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period last year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio (DPR) is 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.